The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Lisdexamfetamine Dimesylate: Linear Dose‐Proportionality, Low Intersubject and Intrasubject Variability, and Safety in an Open‐Label Single‐Dose Pharmacokinetic Study in Healthy Adult Volunteers
Abstract
The pharmacokinetics of lisdexamfetamine dimesylate, a long‐acting prodrug stimulant, and its active moiety, d‐amphetamine, including dose‐proportionality and variability, were assessed in 20 healthy adults. Subjects received a single dose, sequentially, of 50, 100, 150, 200, and 250 mg of lisdexamfetamine dimesylate. Plasma lisdexamfetamine dimesylate and d‐amphetamine were measured before dosing and 0.25 to 96 hours postdose. Dose‐proportionality and intersubject and intrasubject variability of pharmacokinetic parameters were examined. Safety assessments included adverse events. All 20 subjects received 50 and 100 mg while 18, 12, and 9 subjects received 150, 200, and 250 mg of lisdexamfetamine dimesylate, respectively. Ten subjects were discontinued during the study for prespecified stopping rules (2 consecutive hourly readings of blood pressure: systolic >160 mm Hg or diastolic >100 mm Hg). Mean maximum observed plasma concentration (C max) and area under the concentration—time curve from time 0 to infinity (AUC 0‐∞) increased linearly and dose‐dependently for d‐amphetamine. Median time to C max ranged from 4 to 6 hours for d‐amphetamine and 1.0 to 1.5 hours for lisdexamfetamine dimesylate. Intersubject and intrasubject variability over doses from 50 to 150 mg was low (<20%) for both C max and AUC 0‐∞. Adverse events included nausea, dizziness, headache, psychomotor hyperactivity, and dysuria. These findings indicate that the pharmacokinetic parameters of d‐amphetamine were dose‐proportional and predictable over a wide range of lisdexamfetamine dimesylate doses.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For all stimu lant formulations, the duration of effect varies from patient to patient 152 .”
From Attention-deficit/hyperactivity disorder (2015) · cites this paper as [152]
In the citing paper
“First, oral administration of LDX results in systemic exposure to d-amphetamine that is proportional to the LDX dose and that exhibits low intraindividual and interindividual variability.2”
From Lisdexamfetamine prodrug activation by peptidase-mediated hydrolysis in the cytosol of red blood cells (2014) · cites this paper as [2]
In the citing paper
“Low interpatient variability of d-amphetamine plasma levels from LDX has been suggested by consistent delivery of d-amphetamine from patient to patient in a study in children with ADHD and, similarly, within and between subjects in a clinical trial in healthy adults. 2,3”
From Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine (2010) · cites this paper as [3]
In the citing paper
“Pharmacokinetic parameters of d-amphetamine from LDX were dose-proportional over a wide range of oral doses, ranging from therapeutic doses to doses three to eight times higher than therapeutic range. 3”
From Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine (2010) · cites this paper as [3]
In the citing paper
“The dual findings of high-capacity absorption and enzymatic conversion may contribute to the consistent and reproducible pharmacokinetic profile of LDX in humans. 2,3”
From Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine (2010) · cites this paper as [3]
Citations
Cites
Attention-deficit hyperactivity disorder
Biederman, J., & Faraone, S. V. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66915-2 · Cited by 1,463
Committee on Quality Improvement, S. O. A.-D. D. (2000) · Pediatrics · doi:10.1542/peds.105.5.1158 · Cited by 1,076
Greenhill, L. L., Pliszka, S., & Dulcan, M. K. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200202001-00003 · Cited by 927
Misuse and Diversion of Stimulants Prescribed for ADHD: A Systematic Review of the Literature
WILENS, T. E., ADLER, L. A., ADAMS, J., SGAMBATI, S., ROTROSEN, J., SAWTELLE, R., UTZINGER, L., & FUSILLO, S. (2008) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e31815a56f1 · Cited by 824
PLISZKA, S. R., CRISMON, M. L., HUGHES, C. W., CORNERS, C. K., EMSLIE, G. J., JENSEN, P. S., McCRACKEN, J. T., SWANSON, J. M., & LOPEZ, M. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000215326.51175.eb · Cited by 442
Biederman, J., Krishnan, S., Zhang, Y., McGough, J. J., & Findling, R. L. (2007) · Clinical Therapeutics · doi:10.1016/s0149-2918(07)80083-x · Cited by 404
Pelham, W. E., Gnagy, E. M., Burrows-Maclean, L., Williams, A., Fabiano, G. A., Morrisey, S. M., Chronis, A. M., Forehand, G. L., Nguyen, C. A., Hoffman, M. T., et al. (2001) · Pediatrics · doi:10.1542/peds.107.6.e105 · Cited by 378
Biederman, J., Boellner, S. W., Childress, A., Lopez, F. A., Krishnan, S., & Zhang, Y. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.04.015 · Cited by 360
de Graaf, R., Kessler, R. C., Fayyad, J., ten Have, M., Alonso, J., Angermeyer, M., Borges, G., Demyttenaere, K., Gasquet, I., de Girolamo, G., et al. (2008) · Occupational and Environmental Medicine · doi:10.1136/oem.2007.038448 · Cited by 355
Adler, L. A., Goodman, D. W., Kollins, S. H., Weisler, R. H., Krishnan, S., Zhang, Y., & Biederman, J. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0903 · Cited by 218
Research works printed but not linked: 1
- Boellner S, Dose‐proportionality and safety of lisdexamfetamine dimesylate in children with attention‐deficit/hyperactivity disorder, Clin Ther
Cited by
Attention-deficit/hyperactivity disorder
Faraone, S. V., Asherson, P., Banaschewski, T., Biederman, J., Buitelaar, J. K., Ramos-Quiroga, J. A., Rohde, L. A., Sonuga-Barke, E. J. S., Tannock, R., & Franke, B. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.20 · Cited by 1,479
Amphetamine, past and present – a pharmacological and clinical perspective
Heal, D. J., Smith, S. L., Gosden, J., & Nutt, D. J. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113482532 · Cited by 617
Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine
Pennick (2010) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s9749 · Cited by 170
Citrome, L. (2015) · International Journal of Clinical Practice · doi:10.1111/ijcp.12639 · Cited by 113
Weisler, R., Young, J., Mattingly, G., Gao, J., Squires, L., Adler, L., & 304 Study Group (2009) · CNS Spectrums · doi:10.1017/s1092852900024056 · Cited by 94
Metadata
- Authors
- Ermer, J., Homolka, R., Martin, P., Buckwalter, M., Purkayastha, J., & Roesch, B.
- Affiliations
- Takeda (United States) (US)
- Corresponding author
- Ermer, James
- ORCID
- Martin, Patrick
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2010-09
- Volume
- 50
- Issue
- 9
- Pages
- 1001-1010
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- 1552-4604
- OpenAlex
- W2012950683
- Cited by
- 72
- References
- 21
- Citations by year
- 2026: 1 · 2024: 5 · 2023: 2 · 2022: 2 · 2021: 3 · 2020: 1 · 2019: 1 · 2018: 4 · 2017: 5 · 2016: 7 · 2015: 6 · 2014: 8 · 2013: 7 · 2012: 6
- FWCI
- 5.45
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- lisdexamfetamine dimesylate, d-amphetamine, pharmacokinetics, dose proportionality, interindividual variability, within-person variability, stimulants, prodrugs, single-dose administration, adverse events, blood pressure
- MeSH terms
- Lisdexamfetamine Dimesylate, Adult, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Blood Pressure, Dextroamphetamine, Dose-Response Relationship, Drug, Electrocardiography, Female, Headache, Humans, Male, Middle Aged, Prodrugs, Pulse, Area Under Curve, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lisdexamfetamine Dimesylate: Linear Dose‐Proportionality, Low Intersubject and Intrasubject Variability, and Safety in an Open‐Label Single‐Dose Pharmacokinetic Study in Healthy Adult Volunteers. https://app.cochat.ai/papers/10.1177/0091270009357346
- The paper
- Ermer, J., Homolka, R., Martin, P., Buckwalter, M., Purkayastha, J., & Roesch, B. (2010). Lisdexamfetamine Dimesylate: Linear Dose‐Proportionality, Low Intersubject and Intrasubject Variability, and Safety in an Open‐Label Single‐Dose Pharmacokinetic Study in Healthy Adult Volunteers. The Journal of Clinical Pharmacology. https://doi.org/10.1177/0091270009357346
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.